Esophageal Cancer Clinical Trials

Showing 1-2 of 2 items
1.
  • CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
  • The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab. Trastuzumab (also called Herceptin) is an antibody that attacks HER2 protein in tumor cells. Bevacizumab (also called Avastin) works by slowing or stopping the growth of cells in cancer tumors by decreasing the blood supply of the tumors. If blood supply is decreased, oxygen and nutrients that are needed for tumor growth are decreased. The chemotherapy used in this trial is called CAPOX, which is an abbreviation of capecitabine and oxaliplatin.
  • Diagnoses: Esophageal Cancer, Gastrointestinal Malignancies, Stomach Cancer
  • Status: Recruiting
2.
Showing 1-2 of 2 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms